Outcome Evaluation of Senior PharmAssist: Reduced Hospital Use with Enrollment in an Innovative Community-Based Program by Herity, Leah

 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©2018 
Leah B. Herity 
ALL RIGHTS RESERVED  
 
iii 
 
 
 
 
ABSTRACT 
 
Leah B. Herity: Outcome Evaluation of Senior PharmAssist: Reduced Hospital Use with 
Enrollment in an Innovative Community-Based Program 
(Under the direction of Anna Schenck) 
 
Poor medication management is associated with increased use of acute health services 
among older adults. Senior PharmAssist is a non-profit community-based program that combines 
medication therapy management (MTM) with services to address medication access and other 
basic needs. An outcome evaluation of Senior PharmAssist was conducted to assess the effect of 
enrollment in the program on acute health services utilization among older adults. The mean 
number of emergency department (ED) visits and hospital admissions declined significantly over 
time among participants enrolled in the program. These results suggest that enrollment in a 
community-based program that addresses medication management and access while 
simultaneously linking older adults with community resources may reduce hospital use.  
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OVERVIEW OF MASTER’S PAPER 
 This program evaluation paper comprises a manuscript being submitted for publication 
and a number of supplemental appendices. The manuscript describes the Senior PharmAssist 
program and its evaluation. A systematic review of literature describing the effects of enrollment 
in medication management programs on acute health services utilization among older adults 
follows in the first appendix. The remaining appendices contain a reflection of the role of public 
health leadership in pharmacy practice, a sub-analysis of the evaluation results by race, and data 
on individuals who were excluded from the evaluation.  
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Senior PharmAssist: An Innovative Program Associated with Decreased Hospital Use 
Background: Poor medication management is associated with increased use of acute health 
services. This problem is worse for older adults with limited incomes who lack access to 
supportive services and appropriate prescription and medical coverage. There is a need for 
community-based programs to help older adults safely obtain and manage medications while 
linking them to resources that address other basic needs, allowing them to remain independent in 
the community.   
Objectives: To describe the Senior PharmAssist program and evaluate the effect of enrollment 
on acute health services utilization.  
Design: Retrospective analysis. 
Setting: A community-based non-profit program in North Carolina. 
Participants: Adults aged 60 and older with incomes at or below 200% of the federal poverty 
level (FPL) who enrolled in the Senior PharmAssist program (N = 191).  
Intervention: Medication therapy management (MTM), tailored community referrals, Medicare 
insurance counseling, and medication copayment assistance provided by Senior PharmAssist.    
Measurements: Frequency of reported emergency department (ED) visits and hospital 
admissions in the previous 12 months. 
Results: The mean number of ED visits declined over time among participants enrolled in the 
program (0.83 at baseline to 0.53 at 24 months, P = .002). Mean hospital admissions also 
decreased after enrollment in the program (0.56 at baseline to 0.4 after 24 months, P = .02). 
Conclusion: Enrollment in a community-based program that helps older adults manage 
medications, connect with community resources, and overcome barriers to medication access 
was associated with a reduction in acute health services utilization.   
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Introduction 
Prescription medications represent an essential component of health care in the United 
States, yet safe use among older adults remains an area of concern. Over 42% of American adults 
aged 65 and older report taking at least 5 prescription medications during the previous month, a 
percentage nearly triple what was reported in the early 1990s.1 Community-dwelling older adults 
who have difficulty managing their medications may be at increased risk for hospitalizations.2 
Studies have shown the use of multiple prescription medications increases the risk of negative 
health outcomes among older adults, including adverse drug reactions and hospitalizations.3–5 
While promoting non-medication strategies and reducing inappropriate medication use are 
essential to optimize medication management, preventing underuse of necessary medications is 
equally important.6 
The potential for older adults to underuse necessary medications has grown as medication 
copayments and coinsurance amounts have increased. Rising out-of-pocket costs for 
medications, either as a result of higher cost-sharing or capped prescription drug benefits, have 
been associated with medication non-adherence.7–11 This finding is particularly pronounced 
among individuals living in lower-income areas.12 Furthermore, studies suggest cost-related 
medication underuse can result in increased hospital admissions,8,13 emergency department (ED) 
visits,8,14,15 and death.8 Medication underuse among older adults may indicate these individuals 
face barriers in accessing other basic necessities. Individuals who report cost-related medication 
underuse are significantly more likely to also experience food insecurity16–19 and report 
limitations in activities of daily living (ADLs) and instrumental activities of daily living 
(IADLs).20 These findings suggest older adults who have difficulty affording medication 
copayments may benefit from interventions linking them with relevant community resources.  
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One approach to addressing concerns associated with prescription medication use among 
older adults is medication therapy management (MTM). The overall purpose of MTM is to 
optimize therapeutic outcomes while minimizing risks.21 This can be achieved through a wide 
variety of services, including comprehensive medication review, collaboration with primary care 
providers, provision of patient education, and development of a medication-related action 
plan.21,22 Previous studies suggest MTM provided to community-dwelling older adults reduces 
inappropriate prescribing and promotes the resolution of medication-related problems.23–25 
However, MTM alone may not adequately address cost-related medication underuse and the 
ability of older adults to connect with community resources.  
Senior PharmAssist is a medication management program for older adults with limited 
incomes that combines MTM with prescription cost-sharing assistance, Medicare insurance 
counseling, and tailored community referrals. A previous evaluation of the program, spanning 
from 1994 to 2001, indicated enrollment in Senior PharmAssist was associated with a number of 
positive outcomes, including reduced acute health services utilization.26 Senior PharmAssist and 
its participant demographics have changed substantially since the program’s inception. In this 
article, we describe the current Senior PharmAssist program and assess program outcomes.   
Senior PharmAssist Program 
Setting 
Senior PharmAssist is an independent, community-based nonprofit program located in 
Durham, North Carolina. Durham County has a population of roughly 306,000, with 11.9% 
being adults aged 65 and older.27 The median household income for older adults is $44,501 with 
8% living in poverty. Among adults aged 65 or older, approximately 61% are white, 32% are 
black or African American, and 2% report Hispanic or Latino origin.28  
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Program Description  
Senior PharmAssist exists to help older adults living in the community remain as healthy 
and independent as possible for as long as possible. It began with a sole focus on optimizing 
medication management but has expanded to include community referrals and Medicare 
insurance counseling. These services are offered to Durham County residents aged 60 and older. 
Senior PharmAssist is open for appointments with participants 40 hours a week. Home visits, 
transportation, and translation services are available.    
Staff  
 During the period of this program evaluation, Senior PharmAssist had the following full-
time employees: executive director, clinical pharmacist, development and communications 
director, community services director, health resources coordinator, and an associate director for 
the later part of the evaluation period. Additionally, the program employed a part-time clinical 
pharmacist and administrative assistant. The roles of staff members are described elsewhere.29   
The executive director is a registered pharmacist who completed a residency in geriatrics and 
whose public health Master’s project led to the development of Senior PharmAssist in 1994.  
Tailored Community Referrals 
 Prior to participants setting appointments for MTM, one of the community resource 
specialists (community services director, health resources coordinator, or associate director) 
documents residency, basic income, age, and specific needs. During the appointment, more 
detailed demographic and financial information is collected from participants or care partners to 
determine eligibility for financial assistance from Senior PharmAssist or other community-based 
or governmental programs. They also gather information on participants’ abilities to complete 
ADLs and IADLs independently in the home and document participants’ insurance coverage and 
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provider preferences. This helps determine which community and governmental referrals are 
offered. Common referrals and applications that are completed include income-based Medicare 
Part B and D assistance programs, emergency food, help with utility bills or large unpaid 
medical bills, transportation, and recreational and social activities.  
MTM 
 Clinical pharmacists meet with program participants every 6 months to provide MTM. 
These services are free-of-charge to Durham County adults aged 60 and older who are Medicare-
eligible and have an income at or below 200% of the federal poverty level (FPL). Participants 
bring their prescription and over-the-counter (OTC) medications to each appointment or the visit 
is rescheduled. The MTM session begins with a brief interview to document chronic conditions, 
medication allergies, vaccination history, and acute health services utilization. 
The pharmacist reviews participants’ prescription and OTC medications, providing 
education on purpose and appropriate administration when needed. Medication adherence is 
assessed through inspection of fill dates and the open-ended question, “How are you taking this 
medication?” Reasons for non-adherence are addressed when necessary. In reviewing 
participants’ current medications, the pharmacist identifies clinically significant drug-related 
problems such as drug-drug interactions, use of medications known to be harmful in older adults, 
duplicate therapies, or intolerable side effects. For participants with certain chronic diseases, a 
brief physical assessment including blood pressure and blood glucose monitoring is conducted. 
All medical history and medication review data are stored within a tailored FileMaker Pro 
database (FileMaker Inc, Santa Clara, CA).  
 A personalized medication action plan is generated for each participant. The action plan 
may contain follow-up items for the participant as well as items for the pharmacist to address, 
 
7 
including contacting the participant’s primary care provider to suggest medication changes, share 
abnormal physical assessment findings, or address affordability concerns. The pharmacist also 
provides each participant with an up-to-date medication list at the end of each visit. The 
medication action plan and medication list are generated and printed using FileMaker Pro. 
Medication Copayment Assistance 
 Direct financial assistance from Senior PharmAssist for medication copayments is 
available to adults aged 60 and older who have a Medicare Part D prescription drug benefit and 
income at or below 200% FPL. Financial assistance is provided in the form of a copayment 
assistance card that can be used at any community pharmacy as a secondary prescription drug 
plan. Retail pharmacies bill Medicare prescription coverage as the primary insurance and bill the 
remaining amount to Senior PharmAssist. A 30-day supply generally costs participants $2 for 
generic and $5 for brand medications. Senior PharmAssist contracts with a pharmacy benefits 
manager that adjudicates all claims based on the program’s geriatric formulary. Local clinicians 
decide what medications the program covers based on safety, effectiveness, and cost-
effectiveness in older adults. Participants must return every 6 months for community referrals 
and MTM to have their eligibility for copayment assistance extended.   
 Medicare Insurance Counseling 
 Senior PharmAssist is the State Health Insurance Assistance Program (SHIP) 
coordinating site for Durham County. Any Medicare-eligible resident of the county may receive 
this service at no charge. Medicare insurance counseling involves tailored discussions that 
describe coverage options based on the individual’s health care utilization, medication needs, 
financial situation, and personal preferences. Senior Pharmacist staff also screen participants for 
eligibility for other governmental programs, such as Medicaid or Medicare Low Income Subsidy 
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(LIS). In the past 5 years, over 55% of individuals with stand-alone Part D plans counseled at 
Senior PharmAssist chose to switch plans. The mean projected annual savings for these 
individuals was $806.30 
Sustainability 
Senior PharmAssist relies on grants and private donations for funding. State grants and 
opportunities promoting health system partnerships with community-based organizations have 
been instrumental in allowing Senior PharmAssist to continue expanding services for older 
adults. The program is not currently contracted to bill Medicare Part D for MTM provided to 
Medicare beneficiaries, but this represents a possible source of income for similar programs.  
Evaluation 
Evaluation Study Design 
 The purpose of this evaluation is to understand current participant demographics and 
assess the effect of enrollment in Senior PharmAssist on acute health services utilization. The 
study included participants who enrolled in Senior PharmAssist between the dates of August 1, 
2011 and March 15, 2017. Participants were included in the evaluation if they were newly 
enrolled in Senior PharmAssist between the above specified dates and had Medicare Part D 
coverage in addition to Senior PharmAssist’s secondary prescription coverage. Participants were 
excluded if they did not have at least one follow-up visit. All participants were followed from 
their initial visit until their most recent follow-up visit occurring before March 15, 2017, up to a 
maximum of 2 years. 
 De-identified demographic and acute health services utilization data were extracted from 
the Senior PharmAssist database. Unique identification (ID) numbers for participants were used 
to facilitate statistical analyses. The investigator responsible for data extraction and analysis did 
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not have access to the key that linked participant ID numbers with participant names. Participant 
responses to the following two questions, asked every 6 months, were assessed to characterize 
acute health services utilization: 1) In the past 12 months, how many times did you visit the 
emergency room of a hospital? 2) How many different times were you in the hospital at least 
overnight in the past 12 months? The University of North Carolina – Chapel Hill Institutional 
Review Board determined this program evaluation did not require approval. 
Statistical Analysis 
 The relationships between length of follow-up and demographic characteristics of 
participants were analyzed using chi-squared and Fisher’s exact tests. The outcome variables of 
interest, ED visits and hospital admissions, were analyzed as both continuous and binary 
variables. Changes in the outcome variables over time were characterized using generalized 
linear mixed effects modeling. The model incorporated random effects at the level of the 
grouping variable, participant ID number. For binary variables, a logit function and Bernoulli 
distribution were used to fit the model. A two-sided alpha error of less than .05 was considered 
statistically significant. All analyses were performed in Stata SE 15 (StataCorp LLC, College 
Station, TX).  
Evaluation Results 
 Three hundred and five individuals enrolled in copayment assistance at Senior 
PharmAssist between August 1, 2011 and March 15, 2017. Of these participants, 114 were 
excluded for attending only an initial baseline visit without subsequent follow-up. Reasons for 
having attended only a baseline visit included: insufficient time for a 6-month follow-up visit 
before the study end date (32.5%), loss to follow-up (24.6%), copayment assistance was no 
longer needed (21.9%), became ineligible for copayment assistance (13.2%), left by choice 
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(4.4%), or death (3.5%). One hundred and ninety-one participants, contributing a total of 3,042 
person-months of follow-up, were included in the analysis. The median length of follow-up was 
18 months. The mean age at baseline of included participants was 69.8 (standard deviation (SD) 
7.5) and 70.7% were female (Table 1). The mean number of chronic conditions was 6.8 (SD 2.5). 
Included and excluded participants did not differ significantly in age, number of chronic 
conditions, or baseline frequency of ED visits or hospital admissions. Length of follow-up was 
not significantly associated with baseline age, gender, race, education, number of medications, or 
number of chronic conditions. 
 The mean numbers of ED visits and hospital admissions in the previous year declined 
significantly over time among participants enrolled in the program (Table 2). When data were 
dichotomized to represent if participants had at least 1 ED visit or hospital admission in the 
previous year, the decreasing trends in utilization persisted (Figure 1). Generalized linear mixed 
effects modeling revealed this trend remained statistically significant for ED visits (P = .003) but 
not for hospital admissions (P = .233), once data were dichotomized. An analysis including only 
those with complete 24-month follow-up data produced results consistent with those from the 
entire sample (Figure 2).  
Discussion 
 Enrollment in Senior PharmAssist was associated with a significant reduction in the 
number of ED visits and hospital admissions reported by program participants. The program 
utilizes an innovative model of pharmaceutical care to provide MTM to older adults while 
simultaneously addressing barriers to medication access through Medicare counseling and 
medication copayment assistance. This model of care recognizes polypharmacy and cost-related 
medication underuse as equally capable of resulting in poor health outcomes among older adults. 
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Through targeting both of these concerns, and addressing the importance of social determinants 
of health by linking participants with community resources to meet basic needs, Senior 
PharmAssist attempts to keep older adults as healthy and independent as possible.  
 These findings reinforce the original outcome evaluation of Senior PharmAssist 
performed approximately 20 years prior, where enrollment in the program was associated with 
significant decreases in ED visits and hospital admissions.26 Since the time of the original 
evaluation, the program has evolved to include a more robust community referral process and 
Medicare counseling. Additionally, the copayment assistance card originally acted as a primary 
prescription insurance but was changed to secondary coverage when Medicare Part D became 
available in 2006. These adjustments to the program, along with the changing demographics of 
Durham over the past two decades, have not appeared to alter the association between enrollment 
in the program and reduced hospital utilization. 
The results of this evaluation are in agreement with a number of previous studies 
suggesting enrollment in community-based MTM programs reduces acute health services 
utilization among older adults.31–33 However, some studies have produced conflicting results 
regarding the effect of MTM on hospital admissions and ED visits. Two large studies evaluating 
the use of telephonic MTM found increases in the use of some acute health services but 
decreases in overall mortality.34,35 These findings suggest the method by which MTM is 
provided, such as by telephone or in a community-based clinic, may influence the program’s 
effects on health outcomes. Recent systematic reviews have also failed to identify a conclusive 
association between MTM and reduced hospitalizations.36,37 However, these studies differ from 
the current evaluation in that Senior PharmAssist provides unique services beyond MTM to help 
older adults overcome barriers to medication access and connect with community resources. 
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The Senior PharmAssist model of care may not be generalizable to all populations of 
older adults. The program’s interventions are likely more important in populations where the cost 
of copayments creates a significant barrier to medication access. A thorough community needs 
assessment and assets mapping should be performed prior to implementation of a similar 
program as some of the functions at Senior PharmAssist may be available in some communities 
but not well coordinated or adequately supported.   
Limitations 
Evaluation of Senior PharmAssist is limited by its observational design. Reported 
hospital utilization for each participant in the year prior to enrollment in Senior PharmAssist was 
compared to hospital utilization over time after enrollment. Since there was no control group, the 
possibility cannot be excluded that the observed decline in acute health services utilization was 
due to some outside factor. However, nationwide data indicate the percentage of adults aged 65 
and older experiencing a hospital admission in the previous year remained fairly constant during 
the study period, changing from 16.2% in 2010 to 15.6% in 2015. These data further suggest this 
percentage increases as individuals age, rising from 12.8% in adults aged 65 to 74 to 18.8% in 
adults aged 75 or older.1 Finally, our study population had a baseline percentage of individuals 
experiencing a hospital admission in the previous year of 33.2%, over double that nationally 
reported for adults aged 65 or older. Therefore, our population was particularly high risk and it is 
unlikely that the significant decrease in acute health services utilization would have occurred 
regardless of program enrollment.  
Only 39% of participants had complete 24-month follow-up data. This creates the 
potential for a relationship between time and hospital utilization to be generated purely on 
healthier participants tending to remain enrolled in the program longer. However, there were no 
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differences in the number of chronic conditions between included and excluded participants and 
no association between number of chronic conditions and length of follow-up. Furthermore, the 
sub-analysis including only participants with complete 24-month follow-up data produced results 
consistent with the entire sample. Finally, the outcomes were susceptible to reporting bias due to 
the use of self-reported data. Participants may have forgotten to report events or reported fewer 
events out of a desire to give a favorable answer. However, it is unlikely that this reporting bias 
would increase consistently over time in such a manner to create a spurious relationship between 
program enrollment and acute health services utilization. In the time after this evaluation was 
conducted, Senior PharmAssist gained access to shared electronic health records (EHR) with 
Duke Health. Future evaluations will utilize this EHR to assess acute health services utilization. 
Conclusion     
 The Senior PharmAssist model of care combines MTM with direct financial assistance, 
community referrals, and Medicare insurance counseling. We found enrollment in these services 
was associated with significantly reduced hospital admissions and ED visits among older adults. 
Our findings contribute to the evidence from other studies showing decreased acute health 
services utilization with enrollment in MTM programs. The variability of findings in studies of 
MTM on health outcomes suggest we have more to learn about how best to deliver care to older 
adults to reduce hospital use. As the population of older adults in the US continues to grow, so 
too will concerns about appropriate medication use. Understanding how to keep community-
dwelling older adults with chronic conditions from unnecessary ED visits and hospital 
admissions is an urgent need. 
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Table 1: Baseline Characteristics of Included Participants (N = 191) 
Characteristic Value 
Age, mean (SD) 69.8 (7.5) 
Female, n (%) 135 (70.7) 
Race, n (%)  
African American 114 (59.7) 
White 69 (36.1) 
Asian or Pacific Islander 3 (1.6) 
Hispanic or Latino 2 (1.1) 
Native American 1 (0.5) 
Other 2 (1.1) 
Education, n (%)  
Less than high school 50 (26.2) 
High school 63 (33) 
More than high school 75 (39.3) 
Unknown 3 (1.6) 
Living situation, n (%)  
Alone 93 (48.7) 
With a spouse 53 (27.8) 
With relatives 36 (18.8) 
Other 7 (3.7) 
Unknown 2 (1.1) 
Length of follow-up, n (%)  
6 months 51 (26.7) 
12 months 39 (20.4) 
18 months 26 (13.6) 
24 months 75 (39.3) 
Prescription medications, mean (SD) 8.1 (3.6) 
Total chronic conditions, mean (SD) 6.8 (2.5) 
Chronic conditions, n (%)  
Hypertension 159 (83.3) 
Arthritis  142 (74.4) 
Hyperlipidemia  135 (70.7) 
Glaucoma, cataracts, or macular 
degeneration 
116 (60.7) 
Diabetes mellitus  99 (51.8) 
Depression or anxiety 89 (46.6) 
Gastroesophageal reflux disease 
(GERD), ulcers, or hiatal hernia 
89 (46.6) 
Respiratory disease 80 (41.9) 
Heart disease 79 (41.4) 
Kidney disease 37 (19.4) 
Thyroid disorder 34 (17.8) 
Osteoporosis 23 (12) 
Liver disease 6 (3.1) 
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Table 2: Mean (SD) Number of ED Visits and Hospital Admissions in the Previous Year among 
Participants Enrolled in Senior PharmAssist 
 Baseline 6 
Months 
12 
Months 
18 
Months 
24 
Months 
Regression 
Coefficient 
P-
value 
ED Visits 0.83 (1.2) 0.60 (1.1) 0.54 (1.1) 0.59 (1) 0.53 (1.1) - 0.01 .002 
Hospital 
Admissions 
0.56 (1) 0.42 (0.9) 0.38 (0.7) 0.44 (0.9) 0.4 (1.1) - 0.01 .02 
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Figure 1: Percent of Participants Experiencing at Least 1 ED Visit (regression coefficient -0.04, 
P = .003) or Hospital Admission (regression coefficient -0.02, P = .23) in the Previous Year 
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Figure 2: Percent of Participants with Complete 24-Month Follow-Up Data (N=75) 
Experiencing at Least 1 ED Visit (regression coefficient -0.04, P = .01) or Hospital Admission 
(regression coefficient -0.02, P = .14) in the Previous Year 
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APPENDIX 1: SYSTEMATIC REVIEW OF LITERATURE 
Background 
 The positive impact of medication review on reducing polypharmacy and inappropriate 
medication use has been established in previous systematic reviews.1,2 While studies often 
describe the effects of medication review on medication use, study outcomes that measure 
changes in acute health services utilization are less frequently reported.3 The current evaluation 
of Senior PharmAssist identified an association between program enrollment and reduced 
hospital admissions and ED visits. Previous systematic reviews have identified little or no effect 
of medication review on clinical outcomes such as hospitalizations.1,4 However, these reviews 
included individuals from a variety of settings, such as long-term care facilities or hospitals. 
Furthermore, they did not necessarily focus on older adults with limited incomes and included 
studies focused primarily on medication management without addressing barriers to access.   
Objective 
To evaluate the effect of medication review on acute health services utilization among 
community-dwelling older adults in the United States. 
Methods 
The following framework was used to develop search terms and identify articles for 
inclusion in the literature review: 
• Population: community-dwelling adults aged 65 or older living in the United States. 
• Intervention: medication review or MTM conducted in a community-based setting such 
as a community pharmacy, clinic, or by telephone in the participant’s home. MTM could 
be coupled with other services, but this was not necessary. 
• Comparison: a control group not receiving medication review is ideal, but not necessary. 
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• Outcome: the frequency of acute health services utilization among program participants. 
This may include emergency department (ED) visits and/or hospital admissions. 
• Methodology: randomized, controlled trials or observational studies.  
Articles were excluded if the study population consisted only of individuals with a certain 
disease state, such as asthma or heart failure. Studies were also excluded if the outcome of 
interest was hospital readmissions, as these studies typically only included patients who had 
recently been discharged from the hospital. These populations were not felt to be representative 
of the general population of community-dwelling older adults. There was no time window during 
which the study must have been published.  
PubMed was searched for relevant articles using the following combination of keywords 
and MESH terms: (“Older adults” OR “older people” OR seniors OR elderly OR aged[MeSH]) 
AND (“Drug Therapy Management” OR “Medication therapy management” OR “Medication 
therapy management”[MeSH] OR “drug utilization review” OR “drug utilisation review” OR 
“drug utilization review”[MeSH]) AND (Hospitalizations OR hospitalization OR hospitalized 
OR “patient admissions” OR “patient admission” OR hospitalization[MeSH] OR “patient 
admission”[MeSH] OR “hospital admission” OR “hospital admissions”). This search returned 
444 articles. Due to the nature of the search terms, a large number of articles were returned that 
involved drug utilization review without MTM actually being the study intervention. These 
articles could generally be excluded as irrelevant by reviewing the title alone. If the title was 
unclear or the study intervention appeared to be MTM, the abstract was reviewed for further 
details. This process of title and abstract review led to the exclusion of 422 articles, 
predominately because the study intervention was not MTM.  
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Full-text review of the remaining 22 articles was conducted, along with manual review of 
the reference list for each article. Review of reference lists identified 1 additional article. Upon 
full-text review, 16 articles were excluded for the following reasons: the program under 
evaluation was not located in the United States (n = 6), the article was a systematic review or 
research protocol (n = 6), the study was limited to only individuals with a specific disease state 
(n = 2), the mean or median age of participants was less than 65 (n = 1), or the study population 
was not community-dwelling (n = 1) (Appendix Figure 1). Due to the limited number of studies 
including only adults aged 65 or older, studies that enrolled younger adults were included as long 
as the study population had a mean or median age of 65 or older. Seven articles were included in 
the literature review. Brief article overviews are located in Appendix Table 1.  
 
 
Appendix Figure 1: Systematic Review Flow Diagram 
Description of Studies 
Hui RL, Yamada BD, Spence MM, Jeong EW, Chan J. Impact of a medicare MTM program: 
Evaluating clinical and economic outcomes. Am J Manag Care. 2014;20(2):43-51. 
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 The purpose of this retrospective, matched cohort study was to evaluate the effect of 
telephone-based MTM on acute health services utilization, mortality, and prescription drug 
costs.5 The study was conducted within the Kaiser Permanente California health system from 
January 2006 to December 2010. The study population consisted of individuals enrolled in a 
Medicare Part D prescription drug benefit who met the following criteria: expected annual drug 
costs of at least $4000, taking at least 2 medications covered by Medicare Part D, and having at 
least 2 chronic conditions. These criteria aligned with those established by the Centers for 
Medicare and Medicaid Services (CMS) for individuals who could receive MTM at no charge 
through their Medicare Part D benefit. In 2010, CMS updated their criteria for eligibility to 
receive MTM services. To maintain agreement with the new CMS eligibility criteria, the study 
updated its eligibility criteria during the final year of recruitment. The 2010 criteria for 
enrollment were as follows: expected annual medication costs of at least $3000, taking at least 5 
medications covered by Medicare Part D, and having at least 3 chronic conditions. 
 From 2006 to 2009, individuals meeting these criteria were offered MTM services and, if 
opting-in, were contacted by telephone by a clinical pharmacist. In 2010, enrollment was 
changed such that all eligible individuals were contacted by phone and could opt-out at that time 
if they weren’t interested in receiving MTM. The intervention consisted of a baseline call to 
gather information on the participant’s current medications. The clinical pharmacist would then 
conduct a comprehensive medication review to identify and resolve medication-related 
problems. Clinical pharmacists were operating under a collaborative practice agreement, thus 
allowing them to independently initiate or alter medications. Pharmacists would also assist in 
coordinating care with other providers, when necessary. Follow-up calls to participants were 
permissible depending on the participants’ needs. 
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 Participants who received MTM were compared to a control group of individuals 
receiving care through Kaiser Permanente who were not eligible for MTM based on the 
aforementioned eligibility criteria. Study participants were matched with controls in a 1:4 ratio 
on the basis of age, gender, geographic location, and diagnostic-cost-group score. Participants 
and controls were followed for a maximum of 1 year. The primary outcome was all-cause 
mortality within 1 year of study enrollment. Secondary outcomes included ED visits, hospital 
admissions, and cost of prescription medications per day. Data were collected using Kaiser 
Permanente electronic information systems as well as California vital statistics death tapes.  
 The study enrolled 34,532 individuals receiving MTM and 138,128 matched controls. 
The mean age of study participants for both MTM and control groups was 75 years old. The 
MTM group had a higher percentage of hospital admissions and ED visits in the year prior to 
study enrollment. In addition, the MTM group had a significantly higher median daily 
medication cost and higher Charlson Comorbidity Index at baseline than the control group.  
 The authors used an adjusted multiple logistic regression model accounting for age, 
gender, region, Charlson Comorbidity Index, and pre-enrollment acute health services utilization. 
The model revealed reduced odds of hospital admissions (OR 0.97, P = .016) and mortality (OR 
0.86, P < .001) among the MTM group compared to the control group. However, the odds of 
experiencing an ED visit were higher in the MTM group (OR 1.17, P < .001). Due to the changes 
to eligibility criteria during the final year of the study, a sub-analysis including only the cohort 
enrolled in 2010 was performed. Results from this sub-analysis were consistent with findings 
from the adjusted model that included the entire study cohort. 
 This study had a number of strengths. The large sample size allowed for detection of 
small changes in hospital admissions and ED visits. This is particularly important when using an 
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outcome such hospital admissions, as it can be a fairly rare event. Another strength was the study 
used controls who were matched on factors that could influence the outcomes of interest, such as 
Charlson Comorbidity Index and age. This matching likely reduced the risk of selection bias 
associated with the non-random process by which participants were enrolled in MTM and 
control groups. The study investigators also had access to comprehensive electronic information 
systems to allow for collecting objective data on hospital admissions and ED visits. This 
minimizes the potential for reporting bias that may be seen with self-reported data. 
 One major limitation of the study was the control group was composed of individuals 
who did not qualify for MTM. Since eligibility criteria for MTM were based on taking multiple 
medications and having numerous chronic conditions, those who were ineligible likely formed a 
healthier population. This was evident in the significantly higher baseline frequency of ED visits 
and hospital admissions in the MTM group compared to the control group. Study investigators 
used an adjusted model in an attempt to control for confounders introduced by these baseline 
differences. However, it is possible that there were covariates affecting the outcomes of interest 
that were not included in the adjusted model. Another limitation is the enrollment criteria 
changed substantially during the study period. Participants enrolled during the final year of the 
study were taking at least 5 medications and had at least 3 chronic conditions, making them a 
particularly high-risk group. Therefore, the study population may not be generalizable to the 
average population of community-dwelling older adults.  
Kiel W, Phillips S. Impact of Pharmacist-Conducted Comprehensive Medication Reviews for 
Older Adult Patients to Reduce Medication Related Problems. Pharm (Basel). 2017;6(1).  
The purpose of this retrospective, post-hoc analysis was to assess the impact of 
comprehensive medication review (CMR) on medication-related problems and acute health 
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services utilization.6 The study intervention took place in a primary care clinic in Southwest 
Michigan from February to March 2014. Patients were selected to receive MTM from a clinical 
pharmacist based on the pharmacist’s opinion of who may benefit from CMR. Patients who 
agreed to receive CMR would meet with the pharmacist one-on-one in the clinic. Pharmacists 
would review medication lists, provide patient education, and collaborate with the patient’s 
primary care provider to adjust medication regimens.  
 The post-hoc analysis included patients who had received CMR at the clinic, were 65 
years or older, and taking at least 5 prescription medications. A control group consisting of 
patients selected for CMR who never received the service due to scheduling barriers was used as 
a comparison. The primary outcome of the study was the difference in medication-related 
problems between intervention and control groups. The study analyzed a number of secondary 
outcomes, including hospital admissions and ED visits in the 90 days following enrollment. 
The study enrolled a total of 52 patients, 26 in each group. The mean age of participants 
in both groups was 76 years old. Participants in the CMR group had a slightly higher average 
number of prescription medications at baseline than the control group (14.2 vs. 12, P = .06). The 
study identified a significant difference in the primary outcome of medication-related problems, 
with more medication-related problems existing in the control group than the group that had 
received CMR (P = .002). There were no statistically significant differences in the frequency of 
ED visits or hospital admissions between the intervention and control groups.  
The main strength of this study was it enrolled only older adults and did not restrict the 
population based on number or type of chronic disease states. This makes the population more 
generalizable to all community-dwelling older adults. However, it is important to note the study 
took place at a single primary care clinic with a single clinical pharmacist providing the 
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intervention. Another strength is the study included a control group that was fairly well matched 
to the intervention group.  
This study had a number of limitations. Most importantly, the sample size was too small 
to detect differences in fairly rare events such as ED visits and hospital admissions. This 
limitation makes the study inconclusive with regards to assessing the effect of CMR on acute 
health services utilization. Additionally, the study only involved a single CMR visit with no 
opportunities for follow-up. It is possible that multiple visits would be required before changes in 
the frequency of hospital admissions or ED visits would be seen. Furthermore, participants were 
only followed for 90 days, which may have been too short of a window to document a significant 
change acute health services utilization. Finally, very little information about the baseline 
characteristics of the study population was provided. In interpreting the results, it is helpful to 
know how high risk the population is for acute health services utilization at baseline. Information 
such as the baseline number of hospital admissions or ED visits, number and frequency of 
chronic diseases, and socioeconomic status of the population would have been useful to know.  
Smith SR, Catellier DJ, Conlisk EA, Upchurch GA. Effect on health outcomes of a community-
based medication therapy management program for seniors with limited incomes. Am J Health 
Syst Pharm. 2006;63(4):372-379. 
 This was the initial evaluation of the Senior PharmAssist program, conducted from June 
1994 to December 2001.7 The program provided comprehensive medication management to 
older adults living in Durham County, North Carolina. The purpose of the evaluation was to 
assess the effect of enrollment in the program on a large number of health outcomes, including 
acute health services utilization. The study population comprised community-dwelling adults 
aged 65 or older who had incomes at or below 150% of the federal poverty level (FPL). Study 
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participants could not have supplemental health insurance or a prescription drug plan at the time 
of enrollment. Senior PharmAssist provided services to older adults as a lone-standing program 
and was not established within a primary care clinic. 
 Once enrolled, participants would meet with a clinical pharmacist for MTM at baseline 
and every 6 months thereafter. Participants also received a prescription benefit card that could be 
used to pay for medications at community pharmacies, similar to a prescription drug plan. 
Additionally, participants were linked with community resources through tailored community 
referrals, if needed. Clinical pharmacists conducting MTM would provide participants with an 
updated medication list at each visit and would contact participants’ primary care physicians to 
make recommendations regarding medications.  
 The outcome of acute health services utilization was assessed by comparing baseline 
utilization to utilization in the 2 years following study enrollment. Self-reported frequencies of 
ED visits and hospital admissions during the previous year were assessed at baseline and every 6 
months thereafter until the study end date. While participants could be followed for a maximum 
of 2 years, not all participants had complete 2-year follow-up data. The study enrolled 506 
participants with a mean age of 76 years old. Approximately 29% of the sample had complete 2-
year follow-up data. The mean number of ED visits during the previous year declined 
significantly over time from baseline to the study end date (P < .001). The mean number of 
hospital admissions also declined significantly (P < .001). 
 One strength of the study was its fairly large sample size of 509 participants. Combined 
with a longer follow-up time of 2 years for some participants, this gave the study adequate power 
to detect changes in the frequency of acute health services utilization. Enrollment in the program 
was not limited to individuals taking a predetermined number of prescription medications or 
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having certain disease states. This helps make the study population more generalizable to a broad 
range of older adult populations. However, it is important to note the study population was 
composed only of individuals with incomes at or below 150% FPL. For this reason, the study 
findings may not be applicable to populations of older adults living in higher-income areas.  
 The study is limited by its lack of a control group, which introduces the potential for an 
unmeasured covariate to be influencing acute health services utilization. The study also used 
self-reported ED visit and hospital admission data, which may have resulted in reporting bias. 
The high rate of attrition also had the potential to introduce bias into the study results, as 
participants who were lost to follow-up may have had worse outcomes than those who remained 
in the study for longer. However, a sensitivity analysis examining the change in acute health 
services utilization by length of follow-up produced results consistent with the overall analysis. 
Since the program included a number of interventions in addition to MTM, it is difficult to tell 
which combination of interventions contributed to reduction in acute health services utilization. 
Finally, the study findings may not be directly applicable to a current population of older adults. 
The study took place in a time when Medicare Part D had yet to be established, meaning older 
adults may have faced different barriers to medication access than today’s population. 
Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J, Weinberger M. Individualized Medication 
Assessment and Planning: Optimizing Medication Use in Older Adults in the Primary Care 
Setting. Pharmacotherapy. 2013;33(8):787-797. 
The purpose of this prospective, observational pilot study was to assess the feasibility and 
impact of a comprehensive MTM program on medication-related problems and acute health 
services utilization among older adults.8 The comprehensive MTM program, termed the 
individualized Medication Assessment and Planning (iMAP) program, was implemented by 
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clinical pharmacists within a primary care practice in North Carolina. The study population 
consisted of community-dwelling adults aged 65 or older who were taking at least 5 prescription 
medications, were English speaking, and were currently receiving care from one of the clinic’s 
primary care physicians. Individuals were identified for enrollment either through referral to the 
program by their primary care physician or by clinical pharmacists identifying the patient as 
someone who may benefit from medication management. 
 The intervention involved an in-person baseline visit with the clinical pharmacist in 
addition to subsequent follow-up visits as deemed appropriate by the pharmacist. During the 
initial visit, demographic information was collected and the patient’s medications were 
comprehensively reviewed for appropriateness. After the visit, the pharmacist would 
communicate recommendations with the patient’s primary care physician and implement any 
necessary changes under a collaborative practice agreement. The pharmacist would then update 
the patient’s medication list, provide patient education, and continue to meet with the patient if 
needed. At a minimum, pharmacists met with study participants 3 and 6 months after their 
baseline visits. The primary outcome was the number of medication-related problems 6 months 
after study enrollment. The secondary outcome was combined ED visits and hospital admissions 
6 months after study enrollment, compared to utilization in the 12 months preceding enrollment. 
Data were collected using an electronic recording system for University of North Carolina 
(UNC) affiliated hospitals and clinics. 
 The study enrolled 64 patients with a mean age of 75 years old. There was a significant 
reduction in the primary outcome of medication-related problems from baseline to 6 months (P < 
.0001). Acute health services utilization decreased from 8.3 ED visits and hospital admission per 
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100 person-months in the 12 months preceding enrollment to 5.4 in the 6 months after 
enrollment. Significance testing was not provided for this outcome.  
One strength of this study is it enrolled a fairly diverse population of older adults and did 
not limit enrollment to individuals with particular types of chronic diseases. Another strength is 
study participants received at least 3 face-to-face visits with clinical pharmacists during the study 
period. This use of frequent follow-up provides evidence that MTM may need to be repeated in 
order to impact outcomes such as acute health services utilization. Finally, the study provided 
abundant information on the baseline characteristics of enrolled patients. These factors are 
important when determining if a similar program could be implemented in a different location.  
The major limitation of this study is its lack of control group. This creates the possibility 
that decreases in acute health services utilization could have occurred in this population 
regardless of enrollment in the iMAP program. Furthermore, participants were not selected at 
random and were given the opportunity to opt-out of enrollment. It is possible that individuals 
who opted-in were more engaged in their health care than the average older adult. The sample 
size was also fairly small and significance testing was not provided for acute health services 
utilization, making it difficult to interpret the results. Finally, study investigators were only able 
to track acute health services utilization at UNC-affiliated institutions. If study participants were 
seen at non-UNC hospitals, these ED visits and hospital admissions would have been missed. 
Romanelli RJ, Leahy A, Jukes T, Ishisaka DY. Pharmacist-led medication management program 
within a patient-centered medical home. Am J Health Syst Pharm. 2015;72(6):453-459.  
This retrospective, propensity-score-matched cohort study evaluated the effect of 
enrollment in a medication management program on health services utilization.9 The study took 
place in a number of primary care clinics in Northern California. The clinic where the medication 
 
34 
management program (MMP) was implemented was a patient-centered medical home (PCMH) 
that employed a clinical pharmacist to provide MTM. Patients were eligible for the retrospective 
analysis if they had at least 2 in-person visits at their primary care clinic between November 1, 
2011 and July 30, 2013. The study population was divided into three groups: 1) MMP cohort – 
patients seen by the clinical pharmacist at the PCMH, 2) PCMH cohort – patients seen at the 
PCMH who were not referred to the clinical pharmacist for MTM, and 3) usual care cohort – 
patients seen at non-PCMH primary care clinics in Northern California. 
Electronic medical records (EMRs) were used to gather health services utilization data. 
The primary outcomes were differences in the rates of ambulatory care visits, hospitalizations, 
and ED visits between groups. Patients in the MMP cohort were matched to controls in the 
PCMH and usual care cohorts in a 1:2 fashion using propensity scores that accounted for a 
number of baseline covariates. There were 281 patients in the MMP cohort who were matched 
with 406 patients in the PCMH cohort and 421 patients in the usual care cohort, giving a total 
sample size of 1,108. The mean age was approximately 65 years old in all cohorts. The cohorts 
were well-matched on most baseline characteristics. However, the MMP group had a 
significantly higher average number of prescription medications and slightly more office visits, 
ED visits, and hospital admissions in the 6 months prior to study enrollment.  
Negative binomial regression models adjusted for propensity-score covariates were used 
to assess primary outcomes. Compared to the PCMH cohort, the MMP cohort had a higher rate 
of ambulatory care visits (IRR 1.19, P = .004), a similar rate of ED visits (IRR 0.79, P = .124), 
and a lower rate of hospitalizations (IRR 0.48, P = .003). Compared to the usual care cohort, the 
MMP cohort had a similar rate of ambulatory care visits (IRR 1.04, P = .479), a lower rate of ED 
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visits (IRR 0.70, P = .004), and a lower rate of hospitalizations (IRR 0.4, P < .001). There were 
no significant differences in health services utilization between PCMH and usual care cohorts.  
 One strength of this study was that it controlled for a potentially major source of 
confounding, the fact that the MMP was implemented in a PCMH. Other studies have shown 
receiving care in a PCMH is associated with reduced acute health services utilization.10,11 
Therefore, it was essential the study investigators compared outcomes in the MMP cohort with 
not only usual care but also PCMH care. Another strength of the study was it matched controls 
using propensity scores that accounted for a number of potential confounders including age, 
duration of follow-up, Charlson Comorbidity Index, type of insurance, health services utilization 
at baseline, and other factors.  
One limitation of the study was the duration of follow-up was unclear. It did not appear 
patients were followed for a designated amount of time. The only reference to duration of 
follow-up made within the article was that all data were censored on December 31, 2013. If the 
duration of follow-up differed for each patient, a mean or median duration of follow-up would 
have been useful to know. Another limitation is the potential for selection bias, with individuals 
who were referred to the MMP differing in unmeasured ways from controls. While selection bias 
can exist because assignment to the MMP cohort was not random, it is likely mitigated by the 
propensity matching of controls. Finally, the study population had a fairly young mean age (65 
years old) and may not be directly applicable to older adults.  
Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy 
initiative. Am J Health Syst Pharm. 2003;60(11):1123-1129. 
 This randomized, controlled trial evaluated the effect of MTM on medication-related 
problems and acute health services utilization among adults receiving care from 3 primary care 
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clinics in rural Alabama.12 Adults were eligible for the study if they were considered at high risk 
for medication-related problems. To be determined high risk, patients had to have 3 or more of 
the following: at least 5 medications, at least 12 doses of medications per day, at least 4 
medications changes in the previous year, at least 3 chronic diseases, a history of non-adherence 
to medications, or a medication requiring therapeutic drug monitoring. Patients were identified 
for enrollment in the study by clinical pharmacists who reviewed medical records at the 
participating primary care clinics. 
 Patients were randomized to an intervention group or standard medical care group. 
Patients in both control and intervention groups underwent baseline and 1-year follow-up 
interviews with the clinical pharmacist. Those in the intervention group received additional 
follow-up visits after the baseline interview during which MTM was provided and therapeutic 
recommendations were made to primary care providers. These visits with the pharmacist 
occurred each time the patient was seen in the clinic for a scheduled office visit. Medical records 
were used to determine the number of ED visits and hospital admissions in the 12 months prior 
to study enrollment. These values were then compared to the frequency of ED visits and hospital 
admissions during the study period.       
 The mean age of the 69 patients included in the analysis was approximately 65 years old. 
There were no significant differences in the mean number of medications, medication 
knowledge, or median level of education between intervention and control groups at baseline. 
The number of hospital admissions in the intervention group decreased from 24 in the year prior 
to study enrollment to 2 in the year after study enrollment. The control group had 11 hospital 
admissions in the year prior to study enrollment and 11 hospital admissions in the year after 
study enrollment. The difference in hospital admissions between groups during the study period 
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was statistically significant (P = .003). The number of ED visits also decreased in the 
intervention group, from 18 prior to enrollment to 4 after enrollment. For the control group, the 
number of ED visits was 6 prior to study enrollment and 6 after enrollment. The difference in ED 
visits between intervention and control groups during the study period was not significant.  
 The major strength of this study was its randomized, controlled design. This design helps 
minimize selection bias and improves internal validity. The presence of a control group also 
reduces the likelihood that decreases in acute health services utilization were due to an 
unmeasured outside factor. Another strength is medical records were used to collect ED visit and 
hospitalization data, thus minimizing the risk of reporting bias. Additionally, the study followed 
patients for a fairly long period of 1 year. This may have helped the study detect differences in 
ED visits and hospital admissions.  
The results of this study are limited in their applicability to a general population of older 
adults because younger adults were included in the analysis and the mean age was only 65 years 
old. Furthermore, the population selected for the study was particularly high risk and may not be 
generalizable to other populations of older adults. The study was also limited by its small sample 
size and multiple pairwise comparisons, making it difficult to interpret the clinical significance 
of the results. Finally, it was unclear from the publication how many follow-up visits patients 
typically had with the clinical pharmacist. This information would be useful to know when trying 
to elucidate if repeated MTM visits are more beneficial than a single visit.   
 Welch EK, Delate T, Chester EA, Stubbings T. Assessment of the impact of medication therapy 
management delivered to home-based Medicare beneficiaries. Ann Pharmacother. 
2009;43(4):603-610. 
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This nonrandomized, controlled trial assessed the impact of MTM provided to Medicare 
beneficiaries on mortality, acute health services utilization, and prescription drug costs.13 The 
study was conducted in community-dwelling older adults receiving care through the Kaiser 
Permanente Colorado (KPCO) network. Medicare beneficiaries were eligible to participate if 
they had at least 2 chronic conditions, were taking at least 5 Medicare Part D-covered 
prescription medications, and were expected to have an annual prescription drug cost of at least 
$4000 during 2006. All Medicare beneficiaries in the KPCO network who met these criteria 
were contacted by the KPCO Clinical Pharmacy Call Center and invited to participate in MTM. 
At that point, beneficiaries had the choice of opting-in or opting-out of MTM.  
Those who opted-in for MTM would receive a comprehensive medication review via 
telephone by a clinical pharmacist. The clinical pharmacist would communicate therapeutic 
recommendations to primary care providers and link participants with clinical services in the 
community. At a minimum, all participants who opted-in would receive 1 phone call from a 
clinical pharmacist to conduct MTM. Unlimited follow-up phone calls were also permitted, 
depending on the participant’s needs. Individuals opting-in for MTM were compared to a control 
group of individuals who were eligible to receive MTM but had chosen to opt-out.  
The primary outcome was all-cause mortality during the 6 months after participants were 
offered MTM services by the Clinical Pharmacy Call Center. Secondary outcomes of the 
percentage of ED visits and hospital admissions were also assessed. Data on mortality and health 
services utilization were collected using EMRs and administrative databases. Health services 
utilization outcomes were assessed using multivariate logistic regression models adjusted for 
age, gender, Chronic Disease Score, and baseline health services utilization.  
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A total of 795 individuals were enrolled in the study, 459 who opted-in for MTM and 339 
who opted-out. The study population had a mean age of 69 years old. Most baseline 
characteristics did not differ significantly between those who opted-in for MTM and those who 
opted-out. However, individuals who opted-in did have slightly higher Chronic Disease Scores 
(8.8 vs. 8.2, P = .016) and a lower percentage of pre-enrollment inpatient hospitalizations (20.7% 
vs. 29.2%, P = .006). In the adjusted model, those who opted-in for MTM had reduced odds of 
death (OR 0.5, 95% CI 0.3 – 0.9) but increased odds of hospitalization (OR 1.4, 95% CI 1.1 – 
2.0). There was no significant difference in the odds of ED visits between groups.  
  One strength of the study is its fairly large sample size, which allowed it to detect 
differences in mortality. Another strength is it enrolled a control group of individuals who met 
the eligibility criteria for MTM but chose not to participate. This method of selecting a control 
group allowed controls to be similar to the intervention group in terms of number of medications, 
number of chronic diseases, and annual medication costs. However, the fact that individuals in 
the control group opted-out of MTM potentially introduces selection bias. It is possible those 
opting-in for MTM were different from those opting-out in ways that weren’t measured by the 
study investigators. For example, individuals opting-in may have been more engaged in their 
care or more likely to utilize health services in general. Statistically controlling for factors such 
as baseline health services utilization may have helped reduce this bias.  
Individuals enrolled in the study had a high chronic disease burden, were taking multiple 
prescription medications, and were expected to incur at least $4000 in annual drug costs. 
Therefore, the study findings may not be generalizable to lower-risk older adult populations. 
While the study enrolled an adequate sample size to reach power for detecting differences in 
mortality, it was not powered to identify changes in secondary outcomes such as health services 
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utilization. For this reason, the finding of no difference in ED visits between control and 
intervention groups should be interpreted with caution. The study also had a follow-up time of 
only 6 months.  
Discussion 
 This systematic review of literature identified 7 articles assessing the effect of medication 
review on acute health services utilization among older adults living in the United States. The 
majority of studies found medication review was associated with reduced hospital admissions. 
Four studies identified a decrease in hospital admissions with a fifth finding a reduction in 
combined hospital admissions and ED visits.5,7–9,12 Of the 2 remaining studies, 1 found a 
significant increase in hospital admissions and the other found no effect.6,13 The effect of 
medication review on ED visits was more inconclusive, with only 3 studies showing decreased 
ED visits and the fourth identifying a reduction in the composite outcome of hospital admissions 
and ED visits.7–9,12 Of the remaining 3 studies, 1 found a significant increase in ED visits and the 
other 2 found no effect.5,6,13  
 Overall, the evidence from this literature review suggests interventions involving MTM 
are associated with reduced acute health services utilization. However, 2 of the 7 articles 
reviewed contradict this conclusion. Using MTM delivered by telephone, Welch et al. (2009) 
found the intervention significantly increased the risk of hospitalization, had no effect on 
frequency of ED visits, and decreased the odds of death. Hui et al. (2014) studied a nearly 
identical intervention involving telephonic MTM and found a decrease in hospital admissions 
and mortality but an increase in ED visits. These findings indicate MTM may link older adults 
with health services in a way that initially increases their utilization but ultimately reduces 
mortality. However, MTM was not associated with increased acute health services utilization in 
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any of the other 5 studies. One notable difference with the Welch et al. (2009) and Hui et al. 
(2014) studies is they used MTM provided by telephone, while the remaining 5 studies in this 
review provided MTM in a clinic or office setting.  
Of the 5 studies that provided MTM in person, 4 found a reduction in hospital admissions 
and ED visits.7–9,12 The fifth study found no difference in acute health services utilization among 
individuals receiving MTM. However, this study had a small sample size of 52 participants and 
was not powered to detect differences in acute health services utilization. The short study 
duration of 90 days resulted in very few hospital admissions (n = 7) and ED visits (n = 13) 
during the study period. As a result of these low event rates, meaningful conclusions about the 
effect of MTM on acute health services utilization in this study cannot be made. The other 4 
studies that provided MTM in person showed clear reductions in acute health services utilization, 
with much less variability in results than the 2 studies using telephonic MTM. Compared to 
MTM provided by telephone, in-person MTM may allow for more comprehensive assessment of 
an individual’s health status and medications, resulting in resolution of drug-related problems 
before they reach a level of severity requiring hospitalization. 
 While the evidence generally suggests MTM reduces acute health services utilization 
among older adults, it is important to note these studies differed substantially in terms of study 
populations. A number of the studies described in this review had inclusion criteria that resulted 
in recruitment of unique populations of older adults. These inclusion criteria involved having a 
minimum number of chronic disease states,5,12,13 minimum number of prescription 
medications,5,6,8,12,13 maximum income,7 or expected high annual medication expenditure.5,13 
Understanding the needs of a particular population of older adults and assessing for barriers to 
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medication access would be essential in determining the services to include when implementing 
a new MTM program. 
The slightly conflicting results found in this systematic review have been documented in 
previous literature. In a systematic review of interventions to reduce polypharmacy among older 
adults, mixed results were found regarding changes in hospital admissions. Of the 5 studies that 
reported hospital admissions as an outcome, 2 found no difference between intervention and 
control groups while 3 noted a decline in hospital admissions among the intervention group.1 
Two other systematic reviews found no significant changes in hospital admissions among those 
receiving medication review.2,4 It is important to note that these reviews involved a wide range of 
studies, including those taking place in hospital settings or outside of the United States. 
 The overall quality of evidence included in this systematic review is fairly low. Only 1 of 
the 7 included studies was a randomized, controlled trial.12 The remaining 6 studies were 
observational, 4 of which had a control group5,6,9,13 and 2 of which did not.7,8 There were also 
some limitations in how hospital admission and ED visit data were collected in the studies. All 
but 1 study gathered acute health services utilization data from medical records or electronic 
databases. While this provides an objective measure of health services utilization, some 
hospitalizations and ED visits may be missed if the participant sought care at an outside hospital. 
For example, Roth et al. (2013) were only able to track hospitalizations and ED visits at UNC-
affiliated hospitals.8 As there are a number of non-UNC hospitals in the area, it is likely some 
hospitalizations went undocumented. Self-reported health services utilization data were used in a 
single study7 and may be more comprehensive but introduce the risk of reporting bias. 
 A number of potential sources of bias were introduced during the completion this 
systematic review. First, PubMed was the only database used to search for articles. Using a 
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single database limits the range of articles that will be returned during the initial search. 
Additionally, only articles that were published in English were considered for inclusion. The 
focus of this systematic review was on programs and interventions taking place in the United 
States. There are a number of studies taking place in other countries that evaluate the effect of 
medication review on acute health services utilization among older adults.14–17 Not including 
these articles may have caused the review to be too limited in scope. Finally, there was only a 
single reviewer determining which articles would be included in the systematic review. Ideally, 
multiple reviewers would make the determination to include or exclude an article.    
Conclusion 
 The majority of studies identified through this systematic review found MTM reduced the 
risk of hospital admissions and ED visits. However, 2 studies that assessed telephonic MTM 
found increases in acute health services utilization but decreases in overall mortality. Studies that 
used MTM provided in person were more consistent in their findings of reduced hospitalizations 
and ED visits. This suggests the method by which MTM is delivered may influence its effects on 
acute health services utilization. The overall quality of evidence from the studies was fairly weak 
and there was substantial heterogeneity between study populations. Further elucidation of the 
most effective style and structure for MTM delivery may require additional well-powered, 
controlled studies.  
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Appendix Table 1: Summary of Selected Articles 
 
Article Study 
Population 
Study Design Intervention Outcomes 
Measured 
Results Strengths and 
Limitations 
Impact of a 
Medicare MTM 
Program: 
Evaluating 
Clinical and 
Economic 
Outcomes5 
 
(Hui et al., 2014) 
Community-
dwelling, high-
risk Part D 
beneficiaries who 
met the following 
criteria: 1) > 2 
chronic diseases, 
1 of which must 
be high risk 2) 
were receiving > 
2 Part D meds 
and 3)  Likely to 
incur > $4000 in 
drug costs/ year 
 
Enrollment 
requirements 
changed during 
the final year of 
the study (had to 
have > 3 chronic 
conditions, > 5 
Part-D meds, and 
incur > $3000 in 
med costs) 
 
Mean age = 75 
 
N = 172,660 
(34,532 receiving 
MTM and 
138,128 controls) 
 
 
 
Retrospective, 
matched-control 
cohort study 
 
Control group:  
those who may or 
may not be 
enrolled in 
Medicare Part-D 
but were not 
eligible for MTM 
based on not 
meeting the 
criteria for 
enrollment 
Pharmacists 
provided MTM 
services via 
telephone. In 
addition to MTM, 
pharmacists 
linked participants 
with other care 
management 
services if needed 
 
Style: telephone 
 
Follow-up: 
baseline and 
unlimited follow-
up as needed 
Primary: all-cause 
mortality within 1 
year of study 
enrollment 
 
Secondary: 
percentage of 
hospital 
admissions and 
ED visits, median 
change in 
prescription cost 
per day  
 
Length of follow-
up: 1 year 
No difference in 
unadjusted all-cause 
mortality between 
groups. The MTM 
group had an absolute 
reduction in hospital 
admissions of 4.1%, 
compared to 2.1% 
increase for controls, 
also greater absolute 
reduction in ED visits in 
the MTM group 
 
In the adjusted model, 
there was a significant 
lower all-cause 
mortality and hospital 
admissions in the MTM 
group. ED visits were 
significantly higher in 
the MTM group than the 
control group. There 
was no difference in 
medication cost per day 
Strengths: control group 
matched on location, age, 
gender, and diagnostic 
cost group; longer 
follow-up time of 1 year; 
data obtained from 
integrated electronic 
recording system; 
enormous sample size of 
34,532 cases and 138,128 
controls; attempted to 
control for selection bias 
by matching controls  
 
Limitations: cases had 
higher baseline frequency 
of hospital admissions 
and ED visits, and higher 
daily medication costs; 
enrollment criteria 
changed during the 
study; particularly high 
risk population  
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Article Study 
Population 
Study Design Intervention Outcomes 
Measured 
Results Strengths and 
Limitations 
Impact of 
Pharmacist-
Conducted 
Comprehensive 
Medication 
Reviews for 
Older Adult 
Patients to 
Reduce 
Medication 
Related 
Problems6 
 
(Kiel & Phillips, 
2017) 
Adults age > 65 
using the primary 
care clinic who 
took > 5 
medications and 
had received 
MTM by the 
clinical 
pharmacist 
 
Mean age = 76 
 
N = 52 (26 in 
each group) 
Retrospective, 
post-hoc analysis 
 
Control group: 
primary care 
clinic patients > 
65 years old, 
taking > 5 
medications, who 
did not receive 
MTM from the 
clinical 
pharmacist 
 
 
MTM with 
clinical 
pharmacist in the 
participant’s 
primary care 
clinic 
 
Style: in-person 
 
Follow-up: 
baseline only 
Primary outcome: 
difference in 
medication-related 
problems 
 
Secondary 
outcomes: number 
of hospitalizations 
and ED visits 
(among others) 
 
Length of follow-
up: 90 days 
Fewer medication-
related problems at 
follow-up in the MTM 
group compared to the 
control group (p=0.002) 
 
No significant 
differences in the 
number of hospital 
admissions or ED visits  
Strengths: ideal study 
population of 
community-dwelling 
older adults who take 
multiple medications; 
had a control group that 
was fairly well-matched 
on age and number of 
medications 
 
Limitations: the small 
sample size made it 
essentially impossible to 
interpret hospitalization 
results, follow-up period 
of 90 days is fairly short, 
only used a one-time 
intervention with no 
subsequent contact, 
health care utilization not 
a primary outcome 
Effect on Health 
Outcomes of a 
Community-
Based Medication 
Therapy 
Management 
Program for 
Seniors with 
Limited Incomes7 
 
(Smith, Catellier, 
Conlisk, & 
Upchurch, 2006) 
Residents of 
Durham, NC who 
were > 65 years 
old,  had incomes 
< 150% of the 
FPL, and did not 
have prescription 
insurance  
 
Mean age = 76 
 
N = 506 
Retrospective 
cohort 
 
Control group: 
none 
Participants 
received MTM, a 
prescription 
insurance card, 
and tailored 
community 
referrals to other 
programs 
 
Style: in-person 
 
Follow-up: 
baseline and 
every 6 months 
 
 
Many outcomes 
studied; including 
change in self-
reported hospital 
admissions and 
ED visits  
 
Length of follow-
up: 2 years 
Significant reductions in 
hospital admissions and 
ED visits from baseline 
to follow-up (p < 0.001 
for both outcomes); 
sensitivity analysis 
indicate that these 
reductions occurred 
regardless of length of 
follow-up 
Strengths: large sample 
size; patients followed 
for up to 2 years; few 
exclusion criteria 
 
Limitations: took place 
before Medicare Part D 
existed so may not be 
applicable in the current 
health care environment; 
high rate of attrition; self-
reported hospital 
admission and ED visit 
data; no control group 
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Article Study 
Population 
Study Design Intervention Outcomes 
Measured 
Results Strengths and 
Limitations 
Individualized 
Medication 
Assessment and 
Planning: 
Optimizing 
Medication Use 
in Older Adults in 
the Primary Care 
Setting8 
 
(Roth et al., 
2013) 
Patients of a 
primary care 
clinic who were 
age > 65, taking > 
5 medications, 
living 
independently in 
the community, 
English speaking, 
and had a 
working 
telephone 
 
Mean age = 75 
 
N = 64 
Prospective, 
observational 
study 
 
Control group: 
none 
Comprehensive 
MTM services 
from a clinical 
pharmacist at the 
primary care 
office; initial visit 
plus follow-up 
visits every 3 
months or more if 
needed   
 
Style: in-person 
 
Follow-up: 
baseline and 
unlimited follow-
up as needed 
Primary: total 
number of 
medication related 
problems at 6 
months 
 
Secondary: 
combined hospital 
admissions and 
ED visits (data 
were collected 12 
months before and 
6 months after the 
date of 
enrollment)  
 
Length of follow-
up: 6 months 
Significant reduction in 
the mean number of 
medication-related 
problems (P<0.0001); 
reduction in combined 
hospital admissions and 
ED visits of 35% (no 
significance testing 
provided)   
Strengths: sample from 
general population at the 
clinic; had complete data 
for hospital admissions 
(no missing data points) 
 
Limitations: short follow-
up period; small sample 
size; no test for 
significance on 
hospitalization results; no 
control group; only had 
access to hospital use 
data through UNC, so 
utilization of other 
hospitals would be 
missed; involved only a 
single site   
Pharmacist-Led 
Medication 
Management 
Program 
Within a Patient-
Centered Medical 
Home9 
 
(Romanelli et al., 
2015) 
Patients being 
seen at a primary 
care clinic in 
California who 
were referred to 
the clinic 
pharmacist by 
their PCP 
 
Mean age = 65 
 
N = 1,108 (281 in 
the MMP group, 
406 in the PCMH 
group, and 421 in 
the usual care 
group) 
 
 
Retrospective, 
propensity score 
matched cohort 
study  
 
Control group: 
those receiving 
care at the clinic 
but not MTM 
(PCMH group) 
and those 
receiving care at 
a different clinic 
and not receiving 
MTM (usual care 
group) 
Medication 
management by a 
clinical 
pharmacist; 
patients received 
at least two face-
to-face visits with 
the pharmacist  
 
Style: in-person 
 
Follow-up: 
baseline and at 
least 1 follow-up 
visit 
Primary: 
differences in rates 
of ambulatory care 
visits, hospital 
admissions, and 
ED visits 
 
Length of follow-
up: unclear, 
recruitment 
occurred from 
Nov. 1, 2011 to 
July 30, 2013. 
Data were 
censored on Dec. 
31, 2013.  
Compared to the PCMH 
group:  MMP had 
significantly higher rate 
of ambulatory care visits 
(p = 0.004), lower rate 
of hospital admissions 
(p = 0.003), and non-
significant lower rate of 
ED visits 
 
Compared to the usual 
care group: MMP group 
had similar ambulatory 
care visits, lower 
hospitalizations (p< 
0.001) and ED visits (p 
= 0.014)  
Strengths: use of EMRs 
to capture hospital use 
data; fairly large sample 
size; included general 
population (not restricted 
to high-risk); control 
group 
 
Limitations: included 
some younger adults; no 
standardized criteria for 
referral to the 
pharmacist; unclear 
average length of follow-
up, appears to be up to a 
maximum of about 1 year 
to 1.5 years; took place at 
a single site  
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Article Study 
Population 
Study Design Intervention Outcomes 
Measured 
Results Strengths and 
Limitations 
Improving 
Primary Care in 
Rural Alabama 
with a Pharmacy 
Initiative12 
 
(Taylor, Byrd, & 
Krueger, 2003) 
Adult patients 
receiving care at 
a participating 
clinic who were 
at high risk for 
medication-
related adverse 
events (> 3 of the 
following risk 
factors: five or 
more 
medications, 12 
or more doses per 
day, 4 or more 
med changes in 
the previous year, 
3 or more chronic 
diseases, a history 
of non-adherence, 
or taking a 
medication that 
requires 
therapeutic drug 
monitoring) 
 
Mean age = 65 
 
N = 69 (33 
intervention and 
36 control) 
 
 
 
 
 
 
 
Randomized, 
controlled trial  
 
Control group: 
standard medical 
care 
MTM with a 
clinical 
pharmacist that 
included 
evaluation of 
medications, 
performing a 
medication 
history, assessing 
adherence, 
providing 
education, and 
making 
therapeutic 
recommendations 
to providers 
 
Style: in-person 
 
Number of visits: 
baseline and again 
at any regularly 
scheduled office 
visits  
Outcomes: clinical 
measures such as 
BP, A1c, INR, 
LDL; number of 
medications 
deemed 
inappropriate, 
patient 
satisfaction, 
medication 
adherence, 
medication 
knowledge, 
health-related 
QOL, medication 
misadventure, 
frequency of ED 
visits and hospital 
admissions 
 
Length of follow-
up: 1 year 
The number of ED visits 
and hospital admissions 
decreased over time in 
the intervention group 
from baseline to follow-
up. In the control group, 
the number of ED visits 
and hospital admissions 
remained constant over 
time. The change in 
hospital admissions 
between groups was 
significant (P = 0.003). 
The decrease in ED 
visits among 
intervention group 
participants was also 
significant (P = 0.044) 
 
Clinical outcomes were 
significantly improved 
among intervention 
group members; also 
improvements in 
inappropriate 
prescribing, adherence, 
and medication 
knowledge 
 
No difference in health-
related QOL between 
groups at 12 months  
Strengths: randomized, 
controlled design reduces 
the risk of bias; measured 
a lot of outcomes 
including objective 
(clinical) endpoints as 
well as subjective 
endpoints (adherence, 
medication knowledge), 
used medical records to 
gather ED and hospital 
admission data, 
population is fairly low-
income but overall is a 
broad sample that didn’t 
focus only on one disease 
state, followed for 1 year  
 
Limitations: small 
sample size, mean age is 
65 but many younger 
individuals were 
included, unclear how 
many follow-up visits 
were typically conducted 
with each participant or if 
this was matched for 
control participants, did 
not control for some 
confounders (such as 
primary care physician)  
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Article Study 
Population 
Study Design Intervention Outcomes 
Measured 
Results Strengths and 
Limitations 
Assessment of 
the Impact of 
Medication 
Therapy 
Management 
Delivered to 
Home-Based 
Medicare 
Beneficiaries13  
 
(Welch, Delate, 
Chester, & 
Stubbings, 2009) 
Community-
dwelling 
Medicare Part D 
beneficiaries who 
met the following 
criteria: 1) had 
two or more 
chronic 
conditions, one of 
which must be 
high risk 2) were 
receiving > 5 Part 
D medications 
and 3) were likely 
to incur at least 
$4000 in costs for 
Part-D covered 
medications per 
year. Participants 
had to opt-in to 
receive MTM 
 
Mean age = 68 
 
N = 795 (459 
opted-in and 336 
opted-out) 
 
Nonrandomized, 
controlled study  
 
Control group: 
individuals 
eligible for MTM 
who had chosen 
to opt-out 
Participants 
received MTM by 
pharmacists via 
telephone. The 
medication review 
involved 
identifying drug-
related problems, 
providing 
education on 
medication use, 
and linking 
participants with 
clinical programs 
if needed. The 
number of follow-
up calls varied 
depending on 
clinical situation 
 
Style: telephone 
 
Follow-up: 
baseline and 
unlimited follow-
up as needed 
Primary: all-cause 
mortality in the 
180 days after 
MTM 
 
Secondary: 
percentage of 
hospitalizations 
and ED visits, cost 
of Part-D covered 
drugs 
 
Length of follow-
up: 6 months 
Those who opted-out of 
MTM services were 
more likely to die during 
the 180-day follow-up 
period (p = 0.044). No 
significant differences in 
the number of hospital 
admissions or ED visits 
between groups. Those 
who opted-in for MTM 
services were more 
likely to have increased 
medication costs. 
 
With adjustment for age, 
sex, chronic disease 
score, and baseline 
healthcare utilization, 
those who opted-in had 
a 40% increase in the 
odds of hospital 
admission, with no 
difference in ED visits    
Strengths: used 
integrated electronic 
medical records to track 
changes in ED visits and 
hospital admissions; had 
a control group 
 
Limitations: selection 
bias; there were 
significant differences in 
chronic disease scores 
and baseline percentage 
of hospitalizations 
between the control and 
intervention groups; 
study population was 
particularly high risk; 
healthcare utilization was 
a secondary outcome 
(study was not powered 
adequately to detect 
differences); follow-up 
time of only 6 months 
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APPENDIX 2: PUBLIC HEALTH LEADERSHIP IN PHARMACY PRACTICE 
Leadership at Senior PharmAssist 
Senior PharmAssist has been helping older adults in Durham County manage 
medications and overcome barriers to medication access for nearly 25 years. Throughout this 
period, Senior PharmAssist has relied on grants and donations to continue providing these 
services free-of-charge to program participants. The sustainability of the program from its 
inception in 1994 until the current day is truly remarkable, especially when considering the ever-
changing demographics and health care needs of older Americans. Strong leadership has been 
essential in allowing Senior PharmAssist to adapt to meet these needs over time.  
 There are many styles of leadership. The most effective style often depends on the 
situation and the specific situational goals.1 For Senior PharmAssist, adaptive leadership has 
played a key role in helping the program remain effective and relevant in a changing health care 
environment. Adaptive leadership focuses on innovation and the development of new strategies 
in order to succeed in unexpected or challenging environments.2 By staying aware of the 
changing needs of older adults over time, Senior PharmAssist has been able to adjust its services 
to target those needs.  
An example of the role of adaptive leadership in Senior PharmAssist can be seen with the 
advent of Medicare Part D in 2006. From 1994 to 2006, Senior PharmAssist provided direct 
financial assistance to participants by acting as a primary payer for prescription medications. In 
2006, older adults became eligible for prescription drug coverage through Medicare Part D and 
Senior PharmAssist transitioned most if its participants to their secondary coverage, lowering 
payments after Part D plans paid first. Senior PharmAssist adjusted a number of other aspects of 
the program in response to Medicare Part D, including: initiating Medicare insurance counseling 
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in 2006, raising the financial eligibility threshold from 150% FPL to 200% FPL in January 2007, 
raising the upper level for assets in March 2007, decreasing the minimum age of eligibility from 
65 to 60 in June 2007, and allowing secondary coverage of Medicare Advantage drug plans in 
March 2008. In March 2015, with the availability of Affordable Care Act subsidies and a local 
community health center providing discounted medications to those not yet eligible for 
Medicare, Senior PharmAssist ended its grandfathered primary drug coverage for some program 
participants. These changes reflect how Senior PharmAssist leadership adapted the program to 
offer new services and serve more people.  
Evidence in support of how adaptive leadership has made Senior PharmAssist remain 
relevant in a changing health care environment can be found in the results of the program’s 
evaluations. The initial evaluation spanned from 1994 to 2001. The results of this evaluation 
indicated that enrollment in the program was associated with a significant decrease in the number 
of hospital admissions and ED visits over time.3 The current evaluation, spanning from 2011 to 
2017, produced nearly identical results. The demographics and baseline level of acute health 
services utilization among participants in the current evaluation were very different from those in 
the initial evaluation. Even with these differences, enrollment in the program still resulted in 
decreases in ED visits and hospital admissions. The program was able to successfully adapt to a 
changing population and continue providing services that effectively reduce hospital use. 
Senior PharmAssist illustrates how clinical interventions alone may not be sufficient to 
alter acute health services utilization, especially for individuals who struggle with limited 
incomes. The program was built using a public health framework, focusing on understanding the 
context of individuals’ lives and how this affects their critical needs. The program addresses 
many aspects of health outside of clinical interventions, including health literacy, social 
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determinants of health, and barriers to medication access. The consistent lowering of acute health 
services utilization seen in the previous and current evaluations demonstrates how a combination 
of public health and clinical interventions can have a significant impact on health outcomes for 
older adults.  
The Need for Public Health Leaders in Pharmacy Practice  
 Executive leadership at Senior PharmAssist provides an example of the type of strong, 
resilient leaders that are needed to drive the pharmacy profession forward. Expanding the scope 
of practice of pharmacists and overcoming barriers to the ability of pharmacists to provide 
patient care continue to be challenges facing the pharmacy profession. To address these 
challenges, pharmacists must prove that their contributions positively affect patient care. This 
will be essential not only in justifying the role of pharmacists on health care teams, such as 
accountable care organizations, but also in advocating for provider status under Medicare Part B.  
Pharmacists with public health training and experience are uniquely poised to become 
leaders in addressing these challenges and drivers of change in the pharmacy profession. Public 
health training gives pharmacists the skills to perform needs assessments, design services to 
address unmet needs, implement services, and evaluate if interventions are having the intended 
consequences. Furthermore, public health training provides pharmacists with a strong foundation 
of knowledge in quality improvement, project management, and leadership. Pharmacists with 
this knowledge have the capacity to design and implement innovative pharmacy services. In 
evaluating these services, they will be able to add to the growing body of evidence supporting 
the fact that pharmacists do improve patient care. It is this type of innovation and focus on 
sharing of knowledge that will be crucial in allowing pharmacists to challenge the current 
boundaries of pharmacy practice.   
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APPENDIX 3: SUB-ANALYSIS OF RESULTS BY RACE 
 A sub-analysis of the study results by race was performed to determine if the effects of 
program enrollment were consistent across racial groups. Participants who did not identify as 
either African American or white were excluded from this analysis (n = 8), as the sample size 
was too small to allow for meaningful comparison. The baseline characteristics of African 
American (n = 114) and white (n = 69) participants are compared in Appendix Table 2. 
Differences between groups were assessed using t-tests and Wilcoxon Rank Sum tests for 
normally and non-normally distributed data, respectively. White participants were slightly older 
than African American participants and had significantly more chronic conditions at baseline. 
The most prevalent chronic conditions varied substantially between groups. There were no 
significant differences in level of education or number of prescription medications.  
   Trends in acute health services utilization were assessed using generalized linear mixed 
effects modeling. The mean number of ED visits in both groups declined from baseline to 24 
months of follow-up (Appendix Table 3). This decline was more marked among African 
Americans and reached statistical significance (P = .008). Among white participants, the number 
of ED visits decreased until 12 months of follow-up but increased for the remainder of the study 
period. African American participants also had a significant decrease in hospital admissions over 
time (P = .02). For white participants, hospital admissions initially declined but began increasing 
at 12 months of follow-up and ultimately ended with a slightly higher mean value than was 
reported at baseline. When data were collapsed into binary form, the declining trends in ED 
visits and hospital admissions over time among African American participants remained present 
(Appendix Figure 1). 
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Appendix Table 2: Baseline Characteristics of Included Participants, Separated by Race  
Characteristic African American  
(N = 114)  
White 
(N = 69) 
P-value 
Age, mean (SD) 69 (7.2) 71.4 (8) .02 
Female, n (%) 79 (69.3) 51 (73.9)  
Years of education, mean (SD) 12.4 (2.4) 12.5 (2.8) .84 
Education, n (%)    
Less than high school 33 (29) 16 (23.2)  
High school 35 (30.7) 24 (34.8)  
More than high school 44 (38.6) 28 (40.6)  
Unknown 2 (1.8) 1 (1.5)  
Living situation, n (%)    
Alone 51 (44.7) 41 (59.4)  
With a spouse 35 (30.7) 12 (17.4)  
With relatives 25 (21.9) 10 (14.5)  
Other 2 (1.8) 5 (7.3)  
Unknown 1 (1) 1 (1.5)  
Length of follow-up, n (%)    
6 months 30 (26.3) 17 (24.6)  
12 months 25 (21.9) 14 (20.3)  
18 months 16 (14) 10 (14.5)  
24 months 43 (37.7) 28 (40.6)  
Prescription medications, mean (SD) 7.9 (3.7) 8.6 (3.5) .21 
Total chronic conditions, mean (SD) 6.3 (2.3) 7.8 (2.4) <.001 
Chronic conditions, n (%)    
Hypertension 104 (91.2) 49 (71)  
Arthritis  83 (72.8) 53 (76.8)  
Hyperlipidemia  78 (68.4) 51 (73.9)  
Glaucoma, cataracts, or macular 
degeneration 
60 (52.6) 51 (73.9)  
Diabetes mellitus  71 (62.3) 24 (34.8)  
Depression or anxiety 42 (36.8) 45 (65.2)  
Gastroesophageal reflux disease 
(GERD), ulcers, or hiatal hernia 
48 (42.1) 
 
38 (55.1)  
Respiratory disease 41 (36) 39 (56.5)  
Heart disease 44 (38.6) 35 (50.7)  
Kidney disease 20 (17.5) 15 (21.7)  
Thyroid disorder 14 (12.3) 18 (26.1)  
Osteoporosis 5 (4.4) 17 (24.6)  
Liver disease 2 (1.8) 3 (4.4)  
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Appendix Table 3: Mean (SD) number of ED Visits and Hospital Admissions in the Previous 
Year among Participants Enrolled in Senior PharmAssist, Separated by Race 
 Baseline 6 
Months 
12 
Months 
18 
Months 
24 
Months 
Regression 
Coefficient 
P-value 
ED Visits        
African 
American 
0.8  
(1.1) 
0.52 
(0.91) 
0.48 
(0.9) 
0.53 
(0.86) 
0.33 
(0.71) 
-0.01 .008 
White 0.96 
(1.3) 
0.8  
(1.4) 
0.69 
(1.3) 
0.74 
(1.3) 
0.89 
(1.6) 
-0.02 .06 
Hospital 
Admissions 
       
African 
American 
0.49 
(0.92) 
0.32 
(0.63) 
0.35 
(0.57) 
0.31 
(0.59) 
0.16 
(0.43) 
-0.01 .02 
White 0.74 
(1.2) 
0.64 
(1.2) 
0.47 
(0.97) 
0.68 
(1.3) 
0.79 
(1.6) 
-0.01 .26 
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Appendix Figure 2: The Percentage of Participants Experiencing an ED Visit or Hospital 
Admission in the Previous Year, Separated by Race. Regression coefficients and associated P-
values are as follows: ED visits among African Americans (regression coefficient -0.05, P = 
.004), hospital admissions among African Americans (regression coefficient -0.03, P = .15), ED 
visits among whites (regression coefficient -0.03, P = .16), and hospital admissions among 
whites (regression coefficient -0.01, P = .69) 
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APPENDIX 4: DATA ON EXCLUDED PARTICIPANTS 
Appendix Table 4: Baseline Characteristics of Included and Excluded Participants  
Characteristic Included (N = 191) Excluded (N = 114) P-value† 
Current age, mean (SD) 73 (7.7) 71.6 (6.6) .10 
Female, n (%) 135 (70.7) 75 (65.8) .37 
Race, n (%)    
African American 114 (59.7) 63 (55.3) .45 
White 69 (36.1) 41 (36)  
Asian or Pacific Islander 3 (1.6) 4 (3.5)  
Hispanic or Latino 2 (1.1) 2 (1.8)  
Native American 1 (0.5) 0 (0)  
Other 2 (1.1) 4 (3.5)  
Years of education, mean (SD) 12.5 (2.5) 12.8 (2.8) .39 
Education, n (%)    
Less than high school 50 (26.2) 20 (17.5)  
High school 63 (33) 36 (31.6)  
More than high school 75 (39.3) 46 (40.4)  
Unknown 3 (1.6) 12 (10.5)  
Living situation, n (%)    
Alone 93 (48.7) 36 (31.6)  
With a spouse 53 (27.8) 29 (25.4)  
With relatives 36 (18.8) 31 (27.2)  
Other 7 (3.7) 6 (5.3)  
Unknown 2 (1.1) 12 (10.5)  
Total chronic conditions, mean (SD) 6.8 (2.5) 7 (2.7) .45 
Chronic conditions, n (%)    
Hypertension 159 (83.3) 90 (79)  
Arthritis  142 (74.4) 82 (72)  
Hyperlipidemia  135 (70.7) 77 (67.5)  
Glaucoma, cataracts, or macular 
degeneration 
116 (60.7) 66 (57.9)  
Diabetes mellitus  99 (51.8) 58 (50.9)  
Depression or anxiety 89 (46.6) 54 (47.4)  
Gastroesophageal reflux diseases, 
ulcers 
89 (46.6) 48 (42.1)  
Respiratory disease 80 (41.9) 46 (40.4)  
Heart disease 79 (41.4) 56 (49.1)  
Kidney disease 37 (19.4) 34 (29.8)  
Thyroid disorder 34 (17.8) 22 (19.3)  
Osteoporosis 23 (12) 25 (22)  
Liver disease 6 (3.1) 7 (6.1)  
†A t-test was used for continuous variables and a two-sample test of proportions for proportions 
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Appendix Table 5: Acute Health Services Utilization in the 12 Months Prior to Program 
Enrollment for Included and Excluded Study Participants 
Health Service Included (N = 190) Excluded (N = 111) P-value* 
Baseline ED visits    
Mean (SD) 0.83 (1.2) 0.93 (1.2) .59 
Experienced > 1 ED visit, 
number (%) 
93 (49) 55 (49.6) .92 
Baseline hospital admissions    
Mean (SD) 0.56 (1) 0.63 (0.94) .28 
Experienced > 1 hospital 
admission, number (%) 
63 (33.2) 44 (39.6) .26 
* The Wilcoxon rank-sum test was used for continuous variables (t-test produced similar results) 
and a two-sample test of proportions was used for binary variables 
 
